Abbott launches website, widget for psoriasis awareness

Share this article:
Abbott launches website, widget for psoriasis awareness
Abbott launches website, widget for psoriasis awareness

Abbott launched a psoriasis educational website and a widget for download, the latter offering weekly tips and facts delivered to the user's personal desktop.

The widget, which can be downloaded at PsoriasisAnswers.com, also has a tracker that patients and caregivers can use to record and organize symptoms. Prior to a doctor's appointment, the tracker can be printed out and used as an aid to conversation between a patient and doctor, according to a release on the launch. The website and the widget are “completely unbranded,” according to Michelle Johnson, an Abbott spokesperson.

Other tools, such as a “psoriasis answers kit” and Q&A cards, can be received by mail after filling out a survey which asks patients to name what drugs they are taking, what treatments they've previously used, and how satisfied they are with the results.

The website, created by NYC-based Kirshenbaum Bond Senecal + Partners (or KBS+P), also features a testimonial video with Felicia Williams, a school teacher and psoriasis patient. Additionally, visitors to the website can take a survey that identifies behaviors associated with the disease, and cites statistics (from the National Psoriasis Foundation) based on survey responses.

A separate Abbott website, PsoriasisUncovered.com, offers similar information about the disease, but doesn't include many of the tools, or any testimonials, that are included on the PsoriasisAnswers.com site. That site is intended for patients outside of the US, noted Johnson.    

According to the website, some 125 million people worldwide suffer from psoriasis. Abbott is currently in phase 3 with an experimental drug for the disease, called briakinumab or ABT-874. Briakinumab is “on track for regulatory submission this summer,” said Johnson. Humira, a blockbuster and Abbott's best selling product, is indicated for moderate to severe forms of psoriasis, among several other indications.   

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...